#METABOLOMICS WORKBENCH efahy_20230425_000042 DATATRACK_ID:3937 STUDY_ID:ST002621 ANALYSIS_ID:AN004293 PROJECT_ID:PR001020 VERSION 1 CREATED_ON April 25, 2023, 7:56 am #PROJECT PR:PROJECT_TITLE Molecular Transducer of Physical Activity Consortium PR:PROJECT_SUMMARY MoTrPAC is a national research consortium designed to discover and perform PR:PROJECT_SUMMARY preliminary characterization of the range of molecular transducers (the PR:PROJECT_SUMMARY "molecular map") that underlie the effects of physical activity in humans. The PR:PROJECT_SUMMARY program's goal is to study the molecular changes that occur during and after PR:PROJECT_SUMMARY exercise and ultimately to advance the understanding of how physical activity PR:PROJECT_SUMMARY improves and preserves health. Preclinical and clinical studies will examine the PR:PROJECT_SUMMARY systemic effects of endurance and resistance exercise across a range of ages and PR:PROJECT_SUMMARY fitness levels by molecular probing of multiple tissues before and after acute PR:PROJECT_SUMMARY and chronic exercise. This program is the largest targeted NIH investment of PR:PROJECT_SUMMARY funds into the mechanisms of how physical activity improves health and prevents PR:PROJECT_SUMMARY disease. The MoTrPAC program is supported by the NIH Common Fund and is managed PR:PROJECT_SUMMARY by a trans-agency working group representing multiple NIH institutes and PR:PROJECT_SUMMARY centers, led by the NIH Office of Strategic Coordination, National Institute of PR:PROJECT_SUMMARY Arthritis and Musculoskeletal and Skin Diseases, National Institute of Diabetes PR:PROJECT_SUMMARY and Digestive and Kidney Diseases, National Institute on Aging, and National PR:PROJECT_SUMMARY Institute of Biomedical Imaging and Bioengineering. MoTrPAC Steering Committee: PR:PROJECT_SUMMARY Wendy Kohrt, Chair, Russ Tracy, Co-Chair; NIH Program Manager, Concepcion PR:PROJECT_SUMMARY Nierras. Euan Ashley and Matthew Wheeler are the PIs for the Motrpac PR:PROJECT_SUMMARY Bioinformatics / Data Coordination Center. PR:INSTITUTE MoTrPAC PR:LAST_NAME Ashley PR:FIRST_NAME Euan A. PR:ADDRESS 300 Pasteur Dr Rm A265. MC 5319. Stanford CA 94305. USA PR:EMAIL euan@stanford.edu PR:PHONE (650) 498-4900 #STUDY ST:STUDY_TITLE MoTrPAC: Endurance exercise training study in young adult rats, Rat Brown ST:STUDY_TITLE Adipose Powder - Targeted Tricarboxylic Acid Cycle ST:STUDY_SUMMARY The goal of the endurance exercise training study in young adult rats (internal ST:STUDY_SUMMARY code: PASS1B-06) was to perform exercise training studies in adult (6 month) ST:STUDY_SUMMARY F344 rats, and from these rats collect as many tissues as feasible in order to ST:STUDY_SUMMARY provide high quality samples for detailed analysis by chemical analysis sites. ST:STUDY_SUMMARY Tissues were collected from 10-12 rats sedentary control rats concurrent with ST:STUDY_SUMMARY the collection of the 8-week training groups. The 8-week training group and ST:STUDY_SUMMARY controls were from the same cohort and same age at euthanasia (either 8). For ST:STUDY_SUMMARY the older age group, an additional set of controls (n=5-6) were collected with ST:STUDY_SUMMARY the 1-2 week training group. Rats were either sedentary or underwent an exercise ST:STUDY_SUMMARY training program. Rats were exercised on the rodent treadmill 5 days per week ST:STUDY_SUMMARY using a progressive training protocol designed to exercise the rats at ST:STUDY_SUMMARY approximately 70% of VO2max as outlined in the Table on the next page. Training ST:STUDY_SUMMARY was performed no earlier than 10:00 am and no later than 5:00 pm over 5 ST:STUDY_SUMMARY consecutive days per week. Training was initiated with the treadmill set at 70% ST:STUDY_SUMMARY of VO2 max (see tables) and 5 degrees grade for 20 minutes. The duration of ST:STUDY_SUMMARY exercise was increased by one minute each day until day 31 of training (start of ST:STUDY_SUMMARY week 7), when a duration of 50 min was reached. Speed and grade of each training ST:STUDY_SUMMARY session increased in larger increments due to treadmill parameters. The highest ST:STUDY_SUMMARY intensity and duration of training began on day 31. This intensity was ST:STUDY_SUMMARY maintained for the final 10 days of the protocol to ensure steady state had been ST:STUDY_SUMMARY achieved. If any rats were unable to perform at least 4 days of training per ST:STUDY_SUMMARY week they were removed from the study and euthanized. It is important to note ST:STUDY_SUMMARY that the starting treadmill speed varied depending on the sex and age of the ST:STUDY_SUMMARY rat. The initial and maximum speeds were based on VO2max measurements obtained ST:STUDY_SUMMARY during the pre-training testing of the compliant rats. Rats assigned to the ST:STUDY_SUMMARY control group followed a schedule similar to the training group. They were ST:STUDY_SUMMARY placed in one lane on the treadmill for 15 minutes/day, 5 days per week. The ST:STUDY_SUMMARY treadmill was set at 0 m/min at an incline that corresponded to the incline ST:STUDY_SUMMARY being used by the training group. ST:INSTITUTE Mayo Clinic ST:DEPARTMENT Internal Medicine ST:LABORATORY Mayo Clinic Metabolomics Resource Core (MCMRC) ST:LAST_NAME Nair ST:FIRST_NAME K. Sreekumaran ST:ADDRESS 200 1st St SW, Rochester, MN 55902 ST:EMAIL nair@mayo.edu ST:PHONE (507) 284-2511 #SUBJECT SU:SUBJECT_TYPE Mammal SU:SUBJECT_SPECIES Rattus norvegicus SU:TAXONOMY_ID 10116 #SUBJECT_SAMPLE_FACTORS: SUBJECT(optional)[tab]SAMPLE[tab]FACTORS(NAME:VALUE pairs separated by |)[tab]Additional sample data SUBJECT_SAMPLE_FACTORS 90CFE5A4-76FE-4458-A2B1-A66F0B60118E 90232016910 Group:Control | Timepoint:8 weeks of training or control time | Sex:Male raw_file=24feb21_20.D.zip SUBJECT_SAMPLE_FACTORS F0D83B29-8EFA-4CDE-B1AA-2358AC220ECF 90237016910 Group:Control | Timepoint:8 weeks of training or control time | Sex:Male raw_file=24feb21_21.D.zip SUBJECT_SAMPLE_FACTORS FCE9ABE6-B60B-4934-BAE5-56AF8B11ECEC 90239016910 Group:Control | Timepoint:8 weeks of training or control time | Sex:Male raw_file=24feb21_22.D.zip SUBJECT_SAMPLE_FACTORS 0D5071F5-D166-4CF1-BE8B-EB4DF6E04C0E 90251016910 Group:Training | Timepoint:8 weeks of training or control time | Sex:Female raw_file=24feb21_23.D.zip SUBJECT_SAMPLE_FACTORS FC9D810E-D889-4A63-8FF7-9C099F709AE5 90255016910 Group:Training | Timepoint:8 weeks of training or control time | Sex:Female raw_file=24feb21_24.D.zip SUBJECT_SAMPLE_FACTORS 22CEB023-3001-4E2D-9704-D4C651378D27 90256016910 Group:Control | Timepoint:8 weeks of training or control time | Sex:Female raw_file=24feb21_25.D.zip SUBJECT_SAMPLE_FACTORS F9BEE1FA-E2DB-4BE4-A79C-99D585D6FD17 90265016910 Group:Control | Timepoint:8 weeks of training or control time | Sex:Female raw_file=24feb21_26.D.zip SUBJECT_SAMPLE_FACTORS A77AC89A-1D9E-4516-9DA4-2BE99C8126EF 90266016910 Group:Control | Timepoint:8 weeks of training or control time | Sex:Female raw_file=24feb21_27.D.zip SUBJECT_SAMPLE_FACTORS 22D700B9-EDD0-4BC8-8155-EB9C39417F81 90280016910 Group:Training | Timepoint:4 weeks of training | Sex:Male raw_file=24feb21_28.D.zip SUBJECT_SAMPLE_FACTORS 1CA4210C-3CE6-4A5A-996B-673EBDEB3B81 90281016910 Group:Training | Timepoint:4 weeks of training | Sex:Male raw_file=24feb21_29.D.zip SUBJECT_SAMPLE_FACTORS 9F3E1040-D409-421E-B635-2572DC20ED89 90283016910 Group:Training | Timepoint:4 weeks of training | Sex:Male raw_file=24feb21_30.D.zip SUBJECT_SAMPLE_FACTORS 569A9229-04E8-414A-A195-FE9E8F1B66AB 90289016910 Group:Training | Timepoint:4 weeks of training | Sex:Male raw_file=24feb21_31.D.zip SUBJECT_SAMPLE_FACTORS 06FE1060-F317-41ED-A95F-BE88FBAB9D32 90290016910 Group:Training | Timepoint:4 weeks of training | Sex:Male raw_file=24feb21_32.D.zip SUBJECT_SAMPLE_FACTORS 11D18917-6ADA-49CC-8B2A-1BC3C6DEE662 90408016910 Group:Training | Timepoint:4 weeks of training | Sex:Female raw_file=24feb21_33.D.zip SUBJECT_SAMPLE_FACTORS D350D633-8D95-4783-99F2-BB8294D2EC32 90423016910 Group:Training | Timepoint:1 week of training or control time | Sex:Male raw_file=24feb21_34.D.zip SUBJECT_SAMPLE_FACTORS 10E282EB-1DBA-406E-BD5D-81027083A01D 90430016910 Group:Training | Timepoint:1 week of training or control time | Sex:Male raw_file=24feb21_35.D.zip SUBJECT_SAMPLE_FACTORS 4E974304-21EB-42E8-A729-A7FB6B406E64 90439016910 Group:Training | Timepoint:2 weeks of training | Sex:Male raw_file=24feb21_36.D.zip SUBJECT_SAMPLE_FACTORS 6527EC12-E7EB-4F17-BF0A-0AC7CD1819A0 90441016910 Group:Training | Timepoint:2 weeks of training | Sex:Male raw_file=24feb21_37.D.zip SUBJECT_SAMPLE_FACTORS AEB1611A-F29E-43F8-B9F3-A2BC4F9EB504 90444016910 Group:Training | Timepoint:2 weeks of training | Sex:Male raw_file=24feb21_38.D.zip SUBJECT_SAMPLE_FACTORS FDA87A8D-3634-4C42-9A1A-0EA03B58BB01 90449016910 Group:Training | Timepoint:2 weeks of training | Sex:Male raw_file=24feb21_39.D.zip SUBJECT_SAMPLE_FACTORS CDCFA3F1-07ED-4737-A36D-15EFEC325AA5 90450016910 Group:Training | Timepoint:2 weeks of training | Sex:Male raw_file=24feb21_40.D.zip SUBJECT_SAMPLE_FACTORS DC8B35E8-4AA8-4829-8569-F223D069620C 90578016910 Group:Training | Timepoint:2 weeks of training | Sex:Female raw_file=24feb21_41.D.zip SUBJECT_SAMPLE_FACTORS 8904857C-2073-4BBA-AC7C-1EC239E5BFF7 90581016910 Group:Training | Timepoint:2 weeks of training | Sex:Female raw_file=24feb21_42.D.zip SUBJECT_SAMPLE_FACTORS 0409BED3-F9FE-4C06-9920-74F5E5CA04A3 90587016910 Group:Training | Timepoint:2 weeks of training | Sex:Female raw_file=24feb21_44.D.zip SUBJECT_SAMPLE_FACTORS 0559B193-BED3-4170-B045-10A2B6441CB6 90229016910 Group:Control | Timepoint:8 weeks of training or control time | Sex:Male raw_file=24feb21_61.D.zip SUBJECT_SAMPLE_FACTORS 1F9BD644-303F-43E7-94BE-FF6654306F5E 90585016910 Group:Training | Timepoint:2 weeks of training | Sex:Female raw_file=24feb21_65.D.zip #COLLECTION CO:SAMPLE_TYPE Brown adipose #TREATMENT TR:TREATMENT_SUMMARY - #SAMPLEPREP SP:SAMPLEPREP_SUMMARY homogenized in PBS, isotope IS added, deproteinized, 2 steps derivatization with SP:SAMPLEPREP_SUMMARY ethoxamine, MTBSTFA #CHROMATOGRAPHY CH:CHROMATOGRAPHY_SUMMARY Analytes were chromatographically separated with 17 minutes GC gradient CH:CHROMATOGRAPHY_TYPE GC CH:INSTRUMENT_NAME Agilent Intuvo 9000 GC CH:COLUMN_NAME Agilent DB5-MS (30m x 0.25mm, 0.25um) #ANALYSIS AN:ANALYSIS_TYPE MS #MS MS:INSTRUMENT_TYPE Single quadrupole MS:INSTRUMENT_NAME Agilent 5977B HES MSD MS:MS_TYPE EI MS:ION_MODE POSITIVE MS:MS_COMMENTS SIM; peak integration, concentrations calculated #MS_METABOLITE_DATA MS_METABOLITE_DATA:UNITS nano moles per vial MS_METABOLITE_DATA_START Samples 90229016910 90232016910 90237016910 90239016910 90251016910 90255016910 90256016910 90265016910 90266016910 90280016910 90281016910 90283016910 90289016910 90290016910 90408016910 90423016910 90430016910 90439016910 90441016910 90444016910 90449016910 90450016910 90578016910 90581016910 90585016910 Lactate 20.9789 20.5832 24.5789 15.0221 45.0732 27.9658 30.4676 41.2034 44.4416 11.8323 18.9702 41.2105 13.0095 11.4372 16.6159 68.2743 104.179 9.1303 52.8737 10.0604 32.6111 47.3836 63.3698 72.4727 29.9038 Succinate 0.0708 0.0702 0.0783 0.0495 0.0865 0.0592 0.0901 0.0748 0.1157 0.0754 0.0801 0.0773 0.1336 0.1082 0.1012 0.153 0.3075 0.0774 0.2133 0.0691 0.0941 0.0895 0.116 0.1455 0.128 Fumarate 0.4754 0.5163 0.6181 0.4523 0.875 0.5157 0.5455 0.6138 1.3086 1.0115 0.8153 0.8888 0.6909 0.7682 0.638 0.6459 0.7958 0.3408 0.6121 0.3028 0.6206 0.5756 0.6716 0.6596 0.5628 Oxaloacetate nan nan nan nan nan nan nan nan nan nan nan nan nan nan nan nan nan nan nan nan nan nan nan nan nan Ketoglutarate 0.0284 0.0459 0.0347 0.048 0.2107 0.0657 0.1168 0.0527 0.772 0.0409 0.0614 0.1409 0.0678 0.0832 0.1346 0.4125 1.2694 0.0486 0.2987 0.0352 0.2005 0.3501 0.3794 0.5964 0.1949 Malate 0.769 0.92 1.0279 0.708 1.5534 0.7891 0.8705 2.1823 2.4066 1.7881 1.3904 1.3306 1.0782 1.3395 1.0736 1.1326 1.4341 0.5632 1.1181 0.4466 1.0599 0.974 1.1604 1.1004 0.9221 Aspartate 0.5498 0.6595 0.8547 0.9382 1.339 1.1381 1.1916 1.3115 3.267 1.0956 1.1019 0.952 0.7695 1.137 1.443 0.7094 0.8424 0.6612 0.6256 0.4984 0.9609 0.706 1.1424 1.0665 0.9488 2-Hydroxyglutarate 0.01 0.0082 0.0086 0.0089 0.0121 0.0122 0.0129 0.0122 0.0472 0.0096 0.0092 0.0093 0.0094 0.0099 0.0077 0.0179 0.0259 0.0075 0.0115 0.0081 0.0096 0.0095 0.0113 0.0298 0.0126 Glutamate 0.8262 1.3619 0.7588 1.169 2.3464 1.2631 1.7794 2.7731 15.8329 0.9998 1.2195 1.6344 1.7686 1.2579 1.5727 2.2434 3.8763 1.0938 2.629 0.9413 1.4453 1.9948 2.5196 3.0162 2.122 cis-aconitate 0.0189 0.0179 0.0213 0.022 0.0264 0.0251 0.0301 0.035 0.0364 0.0167 0.0157 0.0185 0.0171 0.0174 0.0301 0.0219 0.0235 0.0166 0.019 0.0097 0.0249 0.0211 0.0349 0.0371 0.034 Citrate 0.4071 0.4633 0.6764 0.7769 0.8904 0.9397 0.9734 1.177 0.9563 0.5637 0.5674 0.6446 0.5051 0.5605 1.1416 0.6755 0.5955 0.4934 0.5324 0.3787 0.8192 0.6876 1.115 1.1762 1.1125 Isocitrate 0.0378 0.0403 0.0479 0.0525 0.0631 0.0631 0.0649 0.0782 0.0592 0.0414 0.0405 0.0488 0.0397 0.0377 0.0649 0.0507 0.0525 0.0384 0.0461 0.0319 0.0562 0.0526 0.0845 0.0894 0.0806 MS_METABOLITE_DATA_END #METABOLITES METABOLITES_START metabolite_name formula mz neutral_mass refmet_name rt Lactate C3H6O3 261 90.0317 Lactic acid 4.18 Succinate C4H6O4 289 118.0266 Succinic acid 5.19 Fumarate C4H4O4 287 116.011 Fumaric acid 6.13 Oxaloacetate C4H4O5 346 132.0059 Oxaloacetic acid 8.37 Ketoglutarate C5H6O5 360 146.0215 Oxoglutaric acid 8.37 Malate C4H6O5 419 134.0215 Malic acid 8.93 Aspartate C4H7NO4 418 133.0375 Aspartic acid 9.37 2-Hydroxyglutarate C5H8O5 433 148.114 2-Hydroxyglutaric acid 9.98 Glutamate C5H9NO4 432 147.0532 Glutamic acid 10.58 cis-aconitate C6H6O6 459 174.0164 cis-Aconitic acid 14.08 Citrate C6H8O7 591 192.027 Citric acid 14.09 Isocitrate C6H8O7 591 192.027 Isocitric acid 14.09 METABOLITES_END #END